Standard BioTools Inc.
LAB
$0.67
$0.023.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -4.93% | -11.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.93% | -11.13% | |||
| Cost of Revenue | -18.86% | -4.99% | |||
| Gross Profit | 12.64% | -17.83% | |||
| SG&A Expenses | -11.93% | -26.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.60% | -33.15% | |||
| Operating Income | 16.85% | 57.05% | |||
| Income Before Tax | -46.66% | 33.66% | |||
| Income Tax Expenses | 718.18% | 100.03% | |||
| Earnings from Continuing Operations | -47.17% | -205.22% | |||
| Earnings from Discontinued Operations | -103.69% | 2,532.74% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -121.06% | 558.96% | |||
| EBIT | 16.85% | 57.05% | |||
| EBITDA | 18.13% | 51.87% | |||
| EPS Basic | -120.93% | 553.29% | |||
| Normalized Basic EPS | 51.94% | 47.98% | |||
| EPS Diluted | -120.93% | 553.29% | |||
| Normalized Diluted EPS | 51.94% | 47.98% | |||
| Average Basic Shares Outstanding | 0.69% | 0.82% | |||
| Average Diluted Shares Outstanding | 0.69% | 0.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||